@article {680406,
	title = {Adalimumab for Ocular Inflammation.},
	journal = {Ocul Immunol Inflamm},
	year = {2016},
	month = {2016 Mar 22},
	pages = {1-8},
	abstract = {PURPOSE: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. METHODS: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. RESULTS: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47\%), and scleritis, occurring in 9 patients (28\%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47\%) became completely inactive, and oral prednisone was reduced to <=10 mg/day in 2 of 4 patients (50\%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. CONCLUSIONS: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.},
	issn = {1744-5078},
	doi = {10.3109/09273948.2015.1134581},
	author = {Durrani, Khayyam and Kempen, John H and Ying, Gui-Shuang and Kacmaz, R Oktay and Artornsombudh, Pichaporn and Rosenbaum, James T and Suhler, Eric B and Thorne, Jennifer E and Jabs, Douglas A and Levy-Clarke, Grace A and Nussenblatt, Robert B and Foster, C Stephen and Foster, C Stephen}
}
